How do HER2 mutations differ from HER2 overexpression and gene amplification in terms of their impact on cancer?
How can this differ among cancer types?
What are the incidences of HER2 overexpression across solid tumors? HER2 mutations?
What is your current practice for testing for HER2? What testing methodologies are used? How do they differ and what can you learn from each?
What is the difference between HER2 amplification and IHC score? What are best practices to ensure patients with HER2 amplification aren’t missed?
Does this vary among solid tumors?
How have levels of HER2 expression changed? What percent of patients typically have HER2-low expression?
Is what is known about HER2 expression/mutations from research in breast and other cancer types applicable to other solid tumor types? Are there unique aspects to consider?
How might current understanding of HER2 expression and HER2 mutations in other solid tumors contribute to the development of future targeted therapies or personalized treatment approaches?